Primary bone lymphoma the university of miami experience

Alvaro Alencar, David Pitcher, Gerald Byrne, Izidore S. Lossos

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83%). Fortyone patients (77%) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83% at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p=0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)39-49
Number of pages11
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2010


  • Bone lymphoma
  • Combination chemo-radiation
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Primary bone lymphoma the university of miami experience'. Together they form a unique fingerprint.

Cite this